Skip to main content
GDU LC 2023 Main banner
Back

Patrick Forde, MD

Johns Hopkins University

Dr. Forde is currently Co-Director of the Division of Upper Aerodigestive Malignancies at Johns Hopkins University and directs the multidisciplinary Thoracic Oncology Research Program at the Bloomberg-Kimmel Institute for Cancer Immunotherapy. He also serves as principal investigator for the Johns Hopkins cancer immunobiology biospecimen repository protocol.
He has led development of a clinical-translational research program focused on the immuno-oncology of upper aerodigestive malignancies. Dr. Forde's research examines the role of immunotherapy for the treatment of cancer with a particular focus on translation of promising laboratory findings to the clinic. His early phase studies have led directly to the development of several ongoing phase 3 trials. In 2022, Prof. Forde's work over several years, published in the New England Journal of Medicine, led to the United States FDA approval of neoadjuvant chemo-immunotherapy for the treatment of surgically operable lung cancer. His work on the role of immunotherapy for mesothelioma, published in Nature Medicine in 2021, led to the development of a phase 3 of chemo-immunotherapy for newly diagnosed mesothelioma for which he currently serves as global principal investigator.

Presentation(s):